-
09.30.2021 | Day Zero Diagnostics wins Disruptive Technology Award at the 2021 AACC annual scientific meeting
Award Highlights the Promise of the Company’s New Class of Diagnostics
-
06.17.2021 | HelixBind awarded $3MM NIH Grant to support testing of its RaPID diagnostic platform for invasive nfections associated with sepsis
HelixBind, which is developing an innovative diagnostic platform to revolutionize care for invasive infections such as sepsis, announced today it has been awarded a $3 million grant from the National Institutes of Health (NIH) to support testing of RaPID/BSI
-
03.10.2021 | Pattern Bioscience receives FDA “breakthrough device designation” for Pneumonia Action Panel
Pattern Bioscience, Inc. has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its Pneumonia Action Panel
-
02.11.2021 | Talis Biomedical announces pricing of initial public offering
Talis Biomedical Corporation (Nasdaq: TLIS), a company dedicated to developing innovative molecular diagnostic tests for infectious diseases at the point-of-care, today announced the pricing of its initial public offering of 13,800,000 shares of its common stock at a public offering price of $16.00 per share
Toggle navigation